nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-195-11-66-74nogr-1784Research ArticleОБЗОРREVIEWНарушения нутритивного статуса и способы его коррекции у больных распространенным раком поджелудочной железыNutritional status disorders and methods of their correction in patients with advanced pancreatic cancerhttps://orcid.org/0000-0002-6946-3826КирюковаМ. А.KiryukovaM. A.

Кирюкова Мария Анатольевна, м. н. с. отделения патологии поджелудочной железы и желчных путей

111123, г. Москва, шоссе Энтузиастов, 86с6

Maria A. Kiryukova, MD, Junior Research Fellow, Pancreatic and Biliary Diseases Department

86 bld. 6 Entuziastov shosse, Moscow, 111123

m.kirukova@mknc.ruhttps://orcid.org/0000-0002-6556-7505ДубцоваЕ. А.DubtsovaE. A.

Дубцова Елена Анатольевна, д. м. н., заведующая отделением патологии поджелудочной железы и желчных путей

111123, г. Москва, шоссе Энтузиастов, 86с6

Elena A. Dubtsova, MD, PhD, Chair of Pancreatic and Biliary Diseases Department

86 bld. 6 Entuziastov shosse, Moscow, 111123

https://orcid.org/0000-0002-4556-4681ВинокуроваЛ. В.VinokurovaL. V.

Винокурова Людмила Васильевна, д. м. н., вед. науч. сотр. отделения патологии поджелудочной железы и желчных путей

111123, г. Москва, шоссе Энтузиастов, 86с6

Lyudmila V. Vinokurova, MD, PhD, Leading researcher, Pancreatic and Biliary Diseases Department

86 bld. 6 Entuziastov shosse, Moscow, 111123

https://orcid.org/0000-0002-2480-5191МалыхМ. В.MalykhM. V.

Малых Марина Васильевна, м. н. с. отделения патологии поджелудочной железы и желчных путей

111123, г. Москва, шоссе Энтузиастов, 86с6

Marina V. Malykh, MD, Junior Research Fellow, Pancreatic and Biliary Diseases Department

86 bld. 6 Entuziastov shosse, Moscow, 111123

https://orcid.org/0000-0003-2815-3992БординД. С.BordinD. S.

Бордин Дмитрий Станиславович, д. м. н., заведующий отделом патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта; профессор кафедры пропедевтики внутренних болезней и гастроэнтерологии; профессор кафедры поликлинической терапии и семейной медицины факультета последипломного образования

111123, г. Москва, шоссе Энтузиастов, 86с6

Dmitry S. Bordin, MD, PhD, Head of Department of Pancreatic, Biliary, and Upper Digestive tract disorders; Professor, Chair of Propaedeutics of Internal Diseases and Gastroenterology; Professor, Chair of Outpatient Therapy and Family Medicine, Faculty of Postgraduate Education

86 bld. 6 Entuziastov shosse, Moscow, 11112320–1 Delegatskaya st., Moscow, 1274734 Sovetskaya st., Tver, 170100

Московский клинический научно-практический центр им. А. С. ЛогиноваРоссияMoscow Clinical Research Center named after A. S. LoginovRussian FederationМосковский клинический научно-практический центр им. А. С. Логинова; Московский государственный медико-стоматологический университет им. А. И. Евдокимова; Тверской государственный медицинский университетРоссияMoscow Clinical Research Center named after A. S. Loginov; Moscow State University of Medicine and Dentistry named after A. I. Yevdokimov; Tver State Medical UniversityRussian Federation2021020120220116674Copyright © Кирюкова М.А., Дубцова Е.А., Винокурова Л.В., Малых М.В., Бордин Д.С., 20222022Кирюкова М.А., Дубцова Е.А., Винокурова Л.В., Малых М.В., Бордин Д.С.Kiryukova M.A., Dubtsova E.A., Vinokurova L.V., Malykh M.V., Bordin D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1784

Несмотря на достигнутый прогресс в лекарственном лечении распространенного рака поджелудочной железы, результаты его лечения и исходы заболевания остаются далекими от удовлетворительных. Особенность лечения мальнутриции у таких пациентов представлена сложностью ее генеза и прогрессивно нарастающей степенью ее проявлений. В обзоре представлены механизмы развития нарушения нутритивного статуса и способы их коррекции.

Despite of achieved progress in advanced pancreatic cancer treatment, the disease outcomes remain far from satisfying. The peculiarity of malnutrition treatment in these patients is the result of its causes complexity and progressively growing manifestations extent. The review represents mechanisms of malnutrition and approaches to their treatment.

нутритивный статусмальнутрициярак поджелудочной железыnutritional statusmalnutritionpancreatic cancerReferencesKamisawa T., Wood L. D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73–85. doi: 10.1016/S0140–6736(16)00141–0.Kamisawa T., Wood L. D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73–85. doi: 10.1016/S0140–6736(16)00141–0.Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10–27. doi: 10.14740/wjon1166.Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10–27. doi: 10.14740/wjon1166.Pancreatic Cancer: Statistics. Cancer.Net n. d. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics (accessed June 29, 2020).Pancreatic Cancer: Statistics. Cancer.Net n. d. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics (accessed June 29, 2020).Gärtner S., Krüger J., Aghdassi A. A., Steveling A., Simon P., Lerch M. M., et al. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors. 2016 May;2(4):195–202. doi: 10.1159/000442873.Gärtner S., Krüger J., Aghdassi A. A., Steveling A., Simon P., Lerch M. M., et al. Nutrition in Pancreatic Cancer: A Review. Gastrointest Tumors. 2016 May;2(4):195–202. doi: 10.1159/000442873.Клинические рекомендации Министерства здравоохранения РФ “Недостаточность питания (мальнутриция) у пациентов пожилого и старческого возраста.” 2020.Clinical guidelines of the Ministry of Health of the Russian Federation “Malnutrition (malnutrition) in elderly and senile patients.” 2020. (in Russ.)Bozzetti F., Arends J., Lundholm K., Micklewright A., Zurcher G., Muscaritoli M.; ESPEN. ESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology. Clin Nutr. 2009 Aug;28(4):445–54. doi: 10.1016/j.clnu.2009.04.011.Bozzetti F., Arends J., Lundholm K., Micklewright A., Zurcher G., Muscaritoli M.; ESPEN. ESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology. Clin Nutr. 2009 Aug;28(4):445–54. doi: 10.1016/j.clnu.2009.04.011.Palesty J.A., Dudrick S. J. What we have learned about cachexia in gastrointestinal cancer. Dig Dis. 2003;21(3):198–213. doi: 10.1159/000073337.Palesty J.A., Dudrick S. J. What we have learned about cachexia in gastrointestinal cancer. Dig Dis. 2003;21(3):198–213. doi: 10.1159/000073337.Cederholm T., Bosaeus I., Barazzoni R., Bauer J., Van Gossum A., Klek S., et al. Diagnostic criteria for malnutrition – An ESPEN Consensus Statement. Clin Nutr. 2015 Jun;34(3):335–40. doi: 10.1016/j.clnu.2015.03.001.Cederholm T., Bosaeus I., Barazzoni R., Bauer J., Van Gossum A., Klek S., et al. Diagnostic criteria for malnutrition – An ESPEN Consensus Statement. Clin Nutr. 2015 Jun;34(3):335–40. doi: 10.1016/j.clnu.2015.03.001.Bharadwaj S., Ginoya S., Tandon P., Gohel T. D., Guirguis J., Vallabh H., et al. Malnutrition: Laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf). 2016 Nov;4(4):272–280. doi: 10.1093/gastro/gow013.Bharadwaj S., Ginoya S., Tandon P., Gohel T. D., Guirguis J., Vallabh H., et al. Malnutrition: Laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf). 2016 Nov;4(4):272–280. doi: 10.1093/gastro/gow013.Ferguson M., Capra S., Bauer J., Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition. 1999 Jun;15(6):458–64. doi: 10.1016/s0899–9007(99)00084–2.Ferguson M., Capra S., Bauer J., Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition. 1999 Jun;15(6):458–64. doi: 10.1016/s0899–9007(99)00084–2.Guigoz Y., Vellas B., Garry P. J. Mini nutritional assessment: A practical assessment tool for grading the nutritional state of elderly patients. Facts, Research in Gerontology. 1994;15–59.Guigoz Y., Vellas B., Garry P. J. Mini nutritional assessment: A practical assessment tool for grading the nutritional state of elderly patients. Facts, Research in Gerontology. 1994;15–59.Rubenstein L.Z., Harker J. O., Salvà A., Guigoz Y., Vellas B. Screening for undernutrition in geriatric practice: Developing the Short-Form Mini-Nutritional Assessment (MNA-SF). J Gerontol A Biol Sci Med Sci. 2001 Jun;56(6): M366–72. doi: 10.1093/gerona/56.6.m366.Rubenstein L.Z., Harker J. O., Salvà A., Guigoz Y., Vellas B. Screening for undernutrition in geriatric practice: Developing the Short-Form Mini-Nutritional Assessment (MNA-SF). J Gerontol A Biol Sci Med Sci. 2001 Jun;56(6): M366–72. doi: 10.1093/gerona/56.6.m366.Elia M. Screening for malnutrition: a multidisciplinary responsibility. Development and use of the ‘Malnutrition Universal Screening Tool’ (‘MUST’) for adults. 2003.Elia M. Screening for malnutrition: a multidisciplinary responsibility. Development and use of the ‘Malnutrition Universal Screening Tool’ (‘MUST’) for adults. 2003.Detsky A., McLaughlin Baker J., Johnston N., Whittaker S., Mendelson R., et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr. 1987 Jan-Feb;11(1):8–13. doi: 10.1177/014860718701100108.Detsky A., McLaughlin Baker J., Johnston N., Whittaker S., Mendelson R., et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr. 1987 Jan-Feb;11(1):8–13. doi: 10.1177/014860718701100108.Ottery F.. Scored Patient- Generated Subjective Global Assessment (PG-SGA). 2005.Ottery F.. Scored Patient- Generated Subjective Global Assessment (PG-SGA). 2005.Buzby G.P., Mullen J. L., Matthews D. C., Hobbs C. L., Rosato E. F. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980 Jan;139(1):160–7. doi: 10.1016/0002–9610(80)90246–9.Buzby G.P., Mullen J. L., Matthews D. C., Hobbs C. L., Rosato E. F. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980 Jan;139(1):160–7. doi: 10.1016/0002–9610(80)90246–9.Ignacio De Ulíbarri J, González-Madroño A, De Villar NGP, González P, González B, Mancha A, et al. CONUT: A tool for Controlling Nutritional Status. First validation in a hospital population. Nutr Hosp. 2005 JanFeb;20(1):38–45. PMID: 15762418.Ignacio De Ulíbarri J, González-Madroño A, De Villar NGP, González P, González B, Mancha A, et al. CONUT: A tool for Controlling Nutritional Status. First validation in a hospital population. Nutr Hosp. 2005 JanFeb;20(1):38–45. PMID: 15762418.Galizia G., Lieto E., Auricchio A., Cardella F., Mabilia A., Podzemny V., et al. Naples prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. 2017 Dec;60(12):1273–1284. doi: 10.1097/DCR.0000000000000961.Galizia G., Lieto E., Auricchio A., Cardella F., Mabilia A., Podzemny V., et al. Naples prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. 2017 Dec;60(12):1273–1284. doi: 10.1097/DCR.0000000000000961.Kondrup J., Ramussen H. H., Hamberg O., Stanga Z.; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003 Jun;22(3):321–36. doi: 10.1016/s0261–5614(02)00214–5.Kondrup J., Ramussen H. H., Hamberg O., Stanga Z.; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003 Jun;22(3):321–36. doi: 10.1016/s0261–5614(02)00214–5.Gianotti L., Besselink M. G., Sandini M., Hackert T., Conlon K., Gerritsen A., et al. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018 Nov;164(5):1035–1048. doi: 10.1016/j.surg.2018.05.040.Gianotti L., Besselink M. G., Sandini M., Hackert T., Conlon K., Gerritsen A., et al. Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2018 Nov;164(5):1035–1048. doi: 10.1016/j.surg.2018.05.040.White J.V., Guenter P., Jensen G., Malone A., Schofield M. Consensus Statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: Characteristics Recommended for the Identification and Documentation of Adult Malnutrition (Undernutrition). J Acad Nutr Diet. 2012 May;112(5):730–8. doi: 10.1016/j.jand.2012.03.012.White J.V., Guenter P., Jensen G., Malone A., Schofield M. Consensus Statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: Characteristics Recommended for the Identification and Documentation of Adult Malnutrition (Undernutrition). J Acad Nutr Diet. 2012 May;112(5):730–8. doi: 10.1016/j.jand.2012.03.012.Ferrucci L.M., Bell D., Thornton J., Black G., McCorkle R., Heimburger D. C., et al. Nutritional status of patients with locally advanced pancreatic cancer: A pilot study. Support Care Cancer. 2011 Nov;19(11):1729–34. doi: 10.1007/s00520–010–1011-x.Ferrucci L.M., Bell D., Thornton J., Black G., McCorkle R., Heimburger D. C., et al. Nutritional status of patients with locally advanced pancreatic cancer: A pilot study. Support Care Cancer. 2011 Nov;19(11):1729–34. doi: 10.1007/s00520–010–1011-x.Patel H.J., Patel B. M. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017 Feb 1;170:56–63. doi: 10.1016/j.lfs.2016.11.033.Patel H.J., Patel B. M. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017 Feb 1;170:56–63. doi: 10.1016/j.lfs.2016.11.033.Ryan A.M., Power D. G., Daly L., Cushen S. J., Ní Bhuachalla E., Prado C. M. Cancer- associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016 May;75(2):199–211. doi: 10.1017/S002966511500419X.Ryan A.M., Power D. G., Daly L., Cushen S. J., Ní Bhuachalla E., Prado C. M. Cancer- associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016 May;75(2):199–211. doi: 10.1017/S002966511500419X.Fearon K., Arends J., Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013 Feb;10(2):90–9. doi: 10.1038/nrclinonc.2012.209.Fearon K., Arends J., Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013 Feb;10(2):90–9. doi: 10.1038/nrclinonc.2012.209.Fukawa T., Yan-Jiang B.C., Min-Wen J.C., Jun-Hao E.T., Huang D., Qian C-N., et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med. 2016 Jun;22(6):666–71. doi: 10.1038/nm.4093.Fukawa T., Yan-Jiang B.C., Min-Wen J.C., Jun-Hao E.T., Huang D., Qian C-N., et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med. 2016 Jun;22(6):666–71. doi: 10.1038/nm.4093.Tsoli M., Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab. 2013 Apr;24(4):174–83. doi: 10.1016/j.tem.2012.10.006.Tsoli M., Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab. 2013 Apr;24(4):174–83. doi: 10.1016/j.tem.2012.10.006.Roxburgh C.S.D., McMillan D. C. Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer. 2014 Mar 18;110(6):1409–12. doi: 10.1038/bjc.2014.90.Roxburgh C.S.D., McMillan D. C. Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer. 2014 Mar 18;110(6):1409–12. doi: 10.1038/bjc.2014.90.Mitchell T., Clarke L., Goldberg A., Bishop K. S. Pancreatic Cancer Cachexia: The Role of Nutritional Interventions. Healthcare (Basel). 2019 Jul 9;7(3):89. doi: 10.3390/healthcare7030089.Mitchell T., Clarke L., Goldberg A., Bishop K. S. Pancreatic Cancer Cachexia: The Role of Nutritional Interventions. Healthcare (Basel). 2019 Jul 9;7(3):89. doi: 10.3390/healthcare7030089.Gyan E., Raynard B., Durand J-P., Guily J. L. Saint, Gouy S., Movschin M. L., et al. Malnutrition in Patients With Cancer: Comparison of Perceptions by Pati ents, Relatives, and Physicians – Results of the NutriCancer2012 Study. JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):255–260. doi: 10.1177/0148607116688881.Gyan E., Raynard B., Durand J-P., Guily J. L. Saint, Gouy S., Movschin M. L., et al. Malnutrition in Patients With Cancer: Comparison of Perceptions by Pati ents, Relatives, and Physicians – Results of the NutriCancer2012 Study. JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):255–260. doi: 10.1177/0148607116688881.Fearon K., Strasser F., Anker S. D., Bosaeus I., Bruera E., Fainsinger R. L., et al. Defi nition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011 May;12(5):489–95. doi: 10.1016/S14702045(10)70218–7.Fearon K., Strasser F., Anker S. D., Bosaeus I., Bruera E., Fainsinger R. L., et al. Defi nition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011 May;12(5):489–95. doi: 10.1016/S14702045(10)70218–7.Tan B.H., Birdsell L. A., Martin L., Baracos V. E., Fearon K. C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009 Nov 15;15(22):6973–9. doi: 10.1158/1078–0432.CCR-09–1525.Tan B.H., Birdsell L. A., Martin L., Baracos V. E., Fearon K. C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009 Nov 15;15(22):6973–9. doi: 10.1158/1078–0432.CCR-09–1525.Kurita Y., Kobayashi N., Tokuhisa M., et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019 Jan;19(1):127–135. doi: 10.1016/j.pan.2018.11.001.Kurita Y., Kobayashi N., Tokuhisa M., et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019 Jan;19(1):127–135. doi: 10.1016/j.pan.2018.11.001.Ozola Zalite I., Zykus R., Francisco Gonzalez M., et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatology. 2015 Jan-Feb;15(1):19–24. doi: 10.1016/j.pan.2014.11.006.Ozola Zalite I., Zykus R., Francisco Gonzalez M., et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatology. 2015 Jan-Feb;15(1):19–24. doi: 10.1016/j.pan.2014.11.006.Sandini M., Patiňo M., Ferrone C. R., Alvarez-Pérez C.A., Honselmann K. C., Paiella S., et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018 Sep 1;153(9):809–815. doi: 10.1001/jamasurg.2018.0979.Sandini M., Patiňo M., Ferrone C. R., Alvarez-Pérez C.A., Honselmann K. C., Paiella S., et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018 Sep 1;153(9):809–815. doi: 10.1001/jamasurg.2018.0979.Kurita Y., Kobayashi N., Tokuhisa M., Goto A., Kubota K., Endo I., et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019 Jan;19(1):127–135. doi: 10.1016/j.pan.2018.11.001.Kurita Y., Kobayashi N., Tokuhisa M., Goto A., Kubota K., Endo I., et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019 Jan;19(1):127–135. doi: 10.1016/j.pan.2018.11.001.Naumann P., Eberlein J., Farnia B., Hackert T., Debus J., Combs S. E. Continued weight loss and sarcopenia predict poor outcomes in locally advanced pancreatic cancer treated with chemoradiation. Cancers (Basel). 2019 May 23;11(5):709. doi: 10.3390/cancers11050709.Naumann P., Eberlein J., Farnia B., Hackert T., Debus J., Combs S. E. Continued weight loss and sarcopenia predict poor outcomes in locally advanced pancreatic cancer treated with chemoradiation. Cancers (Basel). 2019 May 23;11(5):709. doi: 10.3390/cancers11050709.Cho W.K., Yu J. I., Park H. C., Lim D. H., Kim T. H., Chie E. K. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Tumori. 2021 Jun;107(3):247–253. doi: 10.1177/0300891620937795.Cho W.K., Yu J. I., Park H. C., Lim D. H., Kim T. H., Chie E. K. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Tumori. 2021 Jun;107(3):247–253. doi: 10.1177/0300891620937795.Uemura S., Iwashita T., Ichikawa H., et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr. 2021 May 28;125(10):1140–1147. doi: 10.1017/S0007114520003463.Uemura S., Iwashita T., Ichikawa H., et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr. 2021 May 28;125(10):1140–1147. doi: 10.1017/S0007114520003463.Salinas-Miranda E., Deniffel D., Dong X., et al. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol. 2021 Nov;31(11):8662–8670. doi: 10.1007/s00330–021–07899–6.Salinas-Miranda E., Deniffel D., Dong X., et al. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol. 2021 Nov;31(11):8662–8670. doi: 10.1007/s00330–021–07899–6.Blauwhoff-Buskermolen S., Ruijgrok C., Ostelo R. W., de Vet H. C.W., Verheul H. M.W., de van der Schueren M. A.E., Langius J. A.E. The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. Support Care Cancer. 2016 Feb;24(2):661–666. doi: 10.1007/s00520-015–2826–2.Blauwhoff-Buskermolen S., Ruijgrok C., Ostelo R. W., de Vet H. C.W., Verheul H. M.W., de van der Schueren M. A.E., Langius J. A.E. The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. Support Care Cancer. 2016 Feb;24(2):661–666. doi: 10.1007/s00520-015–2826–2.Imaoka H., Mizuno N., Hara K., et al. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Pancreas. 2016 Feb;45(2):211–7. doi: 10.1097/MPA.0000000000000446.Imaoka H., Mizuno N., Hara K., et al. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Pancreas. 2016 Feb;45(2):211–7. doi: 10.1097/MPA.0000000000000446.Bye A., Jordhøy M. S., Skjegstad G., Ledsaak O., Iversen P. O., Hjermstad M. J. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013 Jan;21(1):219–27. doi: 10.1007/s00520–012–1514–8.Bye A., Jordhøy M. S., Skjegstad G., Ledsaak O., Iversen P. O., Hjermstad M. J. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013 Jan;21(1):219–27. doi: 10.1007/s00520–012–1514–8.Arends J., Bachmann P., Baracos V., et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11–48. doi: 10.1016/j.clnu.2016.07.015.Arends J., Bachmann P., Baracos V., et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11–48. doi: 10.1016/j.clnu.2016.07.015.Arends J., Baracos V., Bertz H., et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017 Oct;36(5):1187–1196. doi: 10.1016/j.clnu.2017.06.017.Arends J., Baracos V., Bertz H., et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017 Oct;36(5):1187–1196. doi: 10.1016/j.clnu.2017.06.017.Davidson W., Ash S., Capra S., Bauer J.; Cancer Cachexia Study Group. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004 Apr;23(2):239–47. doi: 10.1016/j.clnu.2003.07.001.Davidson W., Ash S., Capra S., Bauer J.; Cancer Cachexia Study Group. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004 Apr;23(2):239–47. doi: 10.1016/j.clnu.2003.07.001.Andersson R., Dervenis C., Haraldsen P., Leveau P. Nutritional aspects in the management of pancreatic cancer. Ann Gastroenterol. 2000;13:221–4.Andersson R., Dervenis C., Haraldsen P., Leveau P. Nutritional aspects in the management of pancreatic cancer. Ann Gastroenterol. 2000;13:221–4.Arends J., Bodoky G., Bozzetti F., et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr. 2006;25:245–59. doi: 10.1016/j.clnu.2006.01.020.Arends J., Bodoky G., Bozzetti F., et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr. 2006;25:245–59. doi: 10.1016/j.clnu.2006.01.020.Mueller T.C., Burmeister M. A., Bachmann J., Martignoni M. E. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014 Jul 28;20(28):9361–73. doi: 10.3748/wjg.v20.i28.9361.Mueller T.C., Burmeister M. A., Bachmann J., Martignoni M. E. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014 Jul 28;20(28):9361–73. doi: 10.3748/wjg.v20.i28.9361.Okusaka T., Okada S., Ishii H., Ikeda M., Kosakamoto H., Yoshimori M. Prognosis of advanced pancreatic cancer patients with reference to calorie intake. Nutr Cancer. 1998;32(1):55–8. doi: 10.1080/01635589809514717.Okusaka T., Okada S., Ishii H., Ikeda M., Kosakamoto H., Yoshimori M. Prognosis of advanced pancreatic cancer patients with reference to calorie intake. Nutr Cancer. 1998;32(1):55–8. doi: 10.1080/01635589809514717.Blum D., Stene G. B., Solheim T. S., et al. Validation of the Consensus-Defi nition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC–CSA). Ann Oncol. 2014 Aug;25(8):1635–42. doi: 10.1093/annonc/mdu086.Blum D., Stene G. B., Solheim T. S., et al. Validation of the Consensus-Defi nition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC–CSA). Ann Oncol. 2014 Aug;25(8):1635–42. doi: 10.1093/annonc/mdu086.Vujasinovic M., Valente R., Del Chiaro M., Permert J., Löhr J. M. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017 Feb 23;9(3):183. doi: 10.3390/nu9030183.Vujasinovic M., Valente R., Del Chiaro M., Permert J., Löhr J. M. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017 Feb 23;9(3):183. doi: 10.3390/nu9030183.Pezzilli R., Caccialanza R., Capurso G., Brunetti O., Milella M., Falconi M. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers (Basel). 2020 Jan 22;12(2):275. doi: 10.3390/cancers12020275.Pezzilli R., Caccialanza R., Capurso G., Brunetti O., Milella M., Falconi M. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers (Basel). 2020 Jan 22;12(2):275. doi: 10.3390/cancers12020275.DiMagno E.P., Go V. L., Summerskill W. H. Relations between Pancreatic Enzyme Outputs and Malabsorption in Severe Pancreatic Insufficiency. N Engl J Med. 1973 Apr 19;288(16):813–5. doi: 10.1056/NEJM197304192881603.DiMagno E.P., Go V. L., Summerskill W. H. Relations between Pancreatic Enzyme Outputs and Malabsorption in Severe Pancreatic Insufficiency. N Engl J Med. 1973 Apr 19;288(16):813–5. doi: 10.1056/NEJM197304192881603.Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013 Nov 14;19(42):7258–66. doi: 10.3748/wjg.v19.i42.7258.Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013 Nov 14;19(42):7258–66. doi: 10.3748/wjg.v19.i42.7258.Dominguez-Muñoz J. E. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018 Sep;34(5):349–354. doi: 10.1097/MOG.0000000000000459.Dominguez-Muñoz J. E. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol. 2018 Sep;34(5):349–354. doi: 10.1097/MOG.0000000000000459.Sabater L., Ausania F., Bakker O. J., et al. Evidence-based guidelines for the management of exocrine pancreatic insufficiency after pancreatic surgery. Ann Surg. 2016 Dec;264(6):949–958. doi: 10.1097/SLA.0000000000001732.Sabater L., Ausania F., Bakker O. J., et al. Evidence-based guidelines for the management of exocrine pancreatic insufficiency after pancreatic surgery. Ann Surg. 2016 Dec;264(6):949–958. doi: 10.1097/SLA.0000000000001732.Iglesia D., Avci B., Kiriukova M., Panic N., Bozhychko M., Sandru V., de-Madaria E., Capurso G. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis. United European Gastroenterol J. 2020 Nov;8(9):1115–1125. doi: 10.1177/2050640620938987.Iglesia D., Avci B., Kiriukova M., Panic N., Bozhychko M., Sandru V., de-Madaria E., Capurso G. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis. United European Gastroenterol J. 2020 Nov;8(9):1115–1125. doi: 10.1177/2050640620938987.Partelli S., Frulloni L., Minniti C., et al. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis. 2012 Nov;44(11):945–51. doi: 10.1016/j.dld.2012.05.017.Partelli S., Frulloni L., Minniti C., et al. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis. 2012 Nov;44(11):945–51. doi: 10.1016/j.dld.2012.05.017.Sikkens E.C., Cahen D. L., de Wit J., Looman C. W., van Eijck C., Bruno M. J. Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function. Br J Surg. 2014 Jan;101(2):109–13. doi: 10.1002/bjs.9342.Sikkens E.C., Cahen D. L., de Wit J., Looman C. W., van Eijck C., Bruno M. J. Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function. Br J Surg. 2014 Jan;101(2):109–13. doi: 10.1002/bjs.9342.Martin- Perez E., Domínguez-Muñoz J.E., BotellaRomero F., Cerezo L., Matute Teresa F., Serrano T., Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol. 2020 Nov;22(11):1963–1975. doi: 10.1007/s12094–020–02350–6.Martin- Perez E., Domínguez-Muñoz J.E., BotellaRomero F., Cerezo L., Matute Teresa F., Serrano T., Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol. 2020 Nov;22(11):1963–1975. doi: 10.1007/s12094–020–02350–6.Bruno M.J., Haverkort E. B., Tijssen G. P., Tytgat G. N., van Leeuwen D. J. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998 Jan;42(1):92–6. doi: 10.1136/gut.42.1.92.Bruno M.J., Haverkort E. B., Tijssen G. P., Tytgat G. N., van Leeuwen D. J. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998 Jan;42(1):92–6. doi: 10.1136/gut.42.1.92.Domínguez-Muñoz J.E., Nieto-Garcia L., López-Díaz J., Lariño-Noia J., Abdulkader I., Iglesias-Garcia J. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: A retrospective analysis. BMC Cancer. 2018 May 5;18(1):534. doi: 10.1186/s12885–018–4439-x.Domínguez-Muñoz J.E., Nieto-Garcia L., López-Díaz J., Lariño-Noia J., Abdulkader I., Iglesias-Garcia J. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: A retrospective analysis. BMC Cancer. 2018 May 5;18(1):534. doi: 10.1186/s12885–018–4439-x.Roberts K.J., Bannister C. A., Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. Pancreatology. 2019 Jan;19(1):114–121. doi: 10.1016/j.pan.2018.10.010.Roberts K.J., Bannister C. A., Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. Pancreatology. 2019 Jan;19(1):114–121. doi: 10.1016/j.pan.2018.10.010.Хатьков И. Е., Маев И. В., Абдулхаков С. Р., Соавт. И. Российский консенсус по экзо- и эндокринной недостаточности поджелудочной железы после хирургического лечения. Терапевтический Архив 2017;89:105–13. https://doi.org/10.26442/terarkh201890813–26.Khatkov I.E., Maev I. V., Abdulkhakov S. R., et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Ter Arkh. 2018 Aug 27;90(8):13–26. (Russian) doi: 10.26442/terarkh201890813–26.Hoff meister A., Mayerle J., Beglinger C., et al. English language version of the S3-consensus guidelines on chronic pancreatitis: Defi nition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol. 2015 Dec;53(12):1447–95. doi: 10.1055/s-0041–107379.Hoff meister A., Mayerle J., Beglinger C., et al. English language version of the S3-consensus guidelines on chronic pancreatitis: Defi nition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol. 2015 Dec;53(12):1447–95. doi: 10.1055/s-0041–107379.De- Madaria E., Abad- González A., Aparicio J. R., Aparisi L, Boadas J, Boix E, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment). Pancreatology. 2013 Jan-Feb;13(1):18–28. doi: 10.1016/j.pan.2012.11.310.De- Madaria E., Abad- González A., Aparicio J. R., Aparisi L, Boadas J, Boix E, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment). Pancreatology. 2013 Jan-Feb;13(1):18–28. doi: 10.1016/j.pan.2012.11.310.Toouli J., Biankin A. V., Oliver M. R., Pearce C. B., Wilson J. S., Wray N. H. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust. 2010 Oct 18;193(8):461–7. doi: 10.5694/j.1326–5377.2010.tb04000.x.Toouli J., Biankin A. V., Oliver M. R., Pearce C. B., Wilson J. S., Wray N. H. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust. 2010 Oct 18;193(8):461–7. doi: 10.5694/j.1326–5377.2010.tb04000.x.Landers A., Muircroft W., Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support Palliat Care. 2016 Mar;6(1):75–9. doi: 10.1136/bmjsp-care-2014–000694.Landers A., Muircroft W., Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support Palliat Care. 2016 Mar;6(1):75–9. doi: 10.1136/bmjsp-care-2014–000694.Caccialanza R., De Lorenzo F., Gianotti L., et al. Nutritional support for cancer patients: still a neglected right? Support Care Cancer. 2017 Oct;25(10):3001–3004. doi: 10.1007/s00520–017–3826–1.Caccialanza R., De Lorenzo F., Gianotti L., et al. Nutritional support for cancer patients: still a neglected right? Support Care Cancer. 2017 Oct;25(10):3001–3004. doi: 10.1007/s00520–017–3826–1.Caccialanza R., Lobascio F., Brugnatelli S., Pedrazzoli P. Nutritional support in pancreatic cancer. Cancer. 2020 Apr 15;126(8):1810–1811. doi: 10.1002/cncr.32713.Caccialanza R., Lobascio F., Brugnatelli S., Pedrazzoli P. Nutritional support in pancreatic cancer. Cancer. 2020 Apr 15;126(8):1810–1811. doi: 10.1002/cncr.32713.Solheim T.S., Laird B. J.A, Balstad T.R, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778–788. doi: 10.1002/jcsm.12201.Solheim T.S., Laird B. J.A, Balstad T.R, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778–788. doi: 10.1002/jcsm.12201.Simpson F., Doig G. S. Parenteral vs. enteral nutrition in the critically ill patient: A meta-analysis of trials using the intention to treat principle. Intensive Care Med. 2005 Jan;31(1):12–23. doi: 10.1007/s00134–004–2511–2.Simpson F., Doig G. S. Parenteral vs. enteral nutrition in the critically ill patient: A meta-analysis of trials using the intention to treat principle. Intensive Care Med. 2005 Jan;31(1):12–23. doi: 10.1007/s00134–004–2511–2.Pelzer U., Arnold D., Gövercin M., et al. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 2010 Mar 9;10:86. doi: 10.1186/1471–2407–10–86.Pelzer U., Arnold D., Gövercin M., et al. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 2010 Mar 9;10:86. doi: 10.1186/1471–2407–10–86.Cotogni P., De Carli L., Passera R., et al. Longitudinal study of quality of life in advanced cancer patients on home parenteral nutrition. Cancer Med. 2017 Jul;6(7):1799–1806. doi: 10.1002/cam4.1111.Cotogni P., De Carli L., Passera R., et al. Longitudinal study of quality of life in advanced cancer patients on home parenteral nutrition. Cancer Med. 2017 Jul;6(7):1799–1806. doi: 10.1002/cam4.1111.Krüger J., Meffert P. J., Vogt L. J., et al. Early parenteral nutrition in patients with biliopancreatic mass lesions, a prospective, randomized intervention trial. PLoS One. 2016 Nov 18;11(11): e0166513. doi: 10.1371/journal.pone.0166513.Krüger J., Meffert P. J., Vogt L. J., et al. Early parenteral nutrition in patients with biliopancreatic mass lesions, a prospective, randomized intervention trial. PLoS One. 2016 Nov 18;11(11): e0166513. doi: 10.1371/journal.pone.0166513.McMillan D.C., O’Gorman P., Fearon K. C., McArdle C.S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer. 1997;76(6):788–90. doi: 10.1038/bjc.1997.463.McMillan D.C., O’Gorman P., Fearon K. C., McArdle C.S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer. 1997;76(6):788–90. doi: 10.1038/bjc.1997.463.Meydani S.N., Lichtenstein A. H., Cornwall S., et al. Immunologic Effects of National Cholesterol Education Panel Step-2 Diets with and without Fish-derived N-3 Fatty Acid Enrichment. J Clin Invest. 1993 Jul;92(1):105–13. doi: 10.1172/JCI116537.Meydani S.N., Lichtenstein A. H., Cornwall S., et al. Immunologic Effects of National Cholesterol Education Panel Step-2 Diets with and without Fish-derived N-3 Fatty Acid Enrichment. J Clin Invest. 1993 Jul;92(1):105–13. doi: 10.1172/JCI116537.Barber M.D, Fearon K.CH., Tisdale M. J., McMillan D.C., Ross J. A. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001;40(2):118–24. doi: 10.1207/S15327914NC402_7.Barber M.D, Fearon K.CH., Tisdale M. J., McMillan D.C., Ross J. A. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001;40(2):118–24. doi: 10.1207/S15327914NC402_7.Wigmore S.J., Ross J. A., Falconer J. S., et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996 Jan;12(1 Suppl): S27–30. doi: 10.1016/0899–9007(96)90014–3.Wigmore S.J., Ross J. A., Falconer J. S., et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996 Jan;12(1 Suppl): S27–30. doi: 10.1016/0899–9007(96)90014–3.Barber M.D., Ross J. A., Voss A. C., Tisdale M. J., Fearon K.CH. The effect of an oral nutritional supplement enriched with fi sh oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999 Sep;81(1):80–6. doi: 10.1038/sj.bjc.6690654.Barber M.D., Ross J. A., Voss A. C., Tisdale M. J., Fearon K.CH. The effect of an oral nutritional supplement enriched with fi sh oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999 Sep;81(1):80–6. doi: 10.1038/sj.bjc.6690654.Werner K., Küllenberg de Gaudry D., Taylor L. A., et al. Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil – a randomized controlled double-blind trial. Lipids Health Dis. 2017 Jun 2;16(1):104. doi: 10.1186/s12944–017–0495–5.Werner K., Küllenberg de Gaudry D., Taylor L. A., et al. Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil – a randomized controlled double-blind trial. Lipids Health Dis. 2017 Jun 2;16(1):104. doi: 10.1186/s12944–017–0495–5.Abe K., Uwagawa T., Haruki K., et al. Effects of ω-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. Anticancer Res. 2018 Apr;38(4):2369–2375. doi: 10.21873/anticanres.Abe K., Uwagawa T., Haruki K., et al. Effects of ω-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. Anticancer Res. 2018 Apr;38(4):2369–2375. doi: 10.21873/anticanres.Bougnoux P., Hajjaji N., Ferrasson M. N., Giraudeau B., Couet C., Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Br J Cancer. 2009 Dec 15;101(12):1978–85. doi: 10.1038/sj.bjc.6605441.Bougnoux P., Hajjaji N., Ferrasson M. N., Giraudeau B., Couet C., Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Br J Cancer. 2009 Dec 15;101(12):1978–85. doi: 10.1038/sj.bjc.6605441.Camargo Cde Q., Mocellin M. C., Pastore Silva Jde A., Fabre M. E., Nunes E. A., Trindade E. B. Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutr Cancer. 2016;68(1):70–6. doi: 10.1080/01635581.2016.1115097.Camargo Cde Q., Mocellin M. C., Pastore Silva Jde A., Fabre M. E., Nunes E. A., Trindade E. B. Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutr Cancer. 2016;68(1):70–6. doi: 10.1080/01635581.2016.1115097.Darwito D., Dharmana E., Riwanto I., et al. Effects of Omega-3 Supplementation on Ki-67 and VEGF Expression Levels and Clinical Outcomes of Locally Advanced Breast Cancer Patients Treated with Neoadjuvant CAF Chemotherapy: A Randomized Controlled Trial Report. Asian Pacific J Cancer Prev. 2019 Mar 26;20(3):911–916. doi: 10.31557/APJCP.2019.20.3.911.Darwito D., Dharmana E., Riwanto I., et al. Effects of Omega-3 Supplementation on Ki-67 and VEGF Expression Levels and Clinical Outcomes of Locally Advanced Breast Cancer Patients Treated with Neoadjuvant CAF Chemotherapy: A Randomized Controlled Trial Report. Asian Pacific J Cancer Prev. 2019 Mar 26;20(3):911–916. doi: 10.31557/APJCP.2019.20.3.911.Newell M., Mazurak V., Postovit L. M., Field C. J. N‐3 long‐chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic acid, and the role of supplementation during cancer treatment: A scoping review of current clinical evidence. Cancers (Basel). 2021 Mar 10;13(6):1206. doi: 10.3390/cancers13061206.Newell M., Mazurak V., Postovit L. M., Field C. J. N‐3 long‐chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic acid, and the role of supplementation during cancer treatment: A scoping review of current clinical evidence. Cancers (Basel). 2021 Mar 10;13(6):1206. doi: 10.3390/cancers13061206.Eley H.L., Russell S. T., Baxter J. H., Mukerji P., Tisdale M. J. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab. 2007 Oct;293(4): E923–31. doi: 10.1152/ajpendo.00314.2007.Eley H.L., Russell S. T., Baxter J. H., Mukerji P., Tisdale M. J. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab. 2007 Oct;293(4): E923–31. doi: 10.1152/ajpendo.00314.2007.May P.E., Barber A., D’Olimpio J.T., Hourihane A., Abumrad N. N. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am J Surg. 2002 Apr;183(4):471–9. doi: 10.1016/s0002-9610(02)00823–1.May P.E., Barber A., D’Olimpio J.T., Hourihane A., Abumrad N. N. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am J Surg. 2002 Apr;183(4):471–9. doi: 10.1016/s0002-9610(02)00823–1.Rathmacher J.A., Nissen S., Panton L., et al. Supplemen tation with a Combination of β- HydroxyβMethylbutyrate (HMB), Arginine, and Glutamine Is Safe and Could Improve Hematological Parameters. JPEN J Parenter Enteral Nutr. 2004 Mar-Apr;28(2):65–75. doi: 10.1177/014860710402800265.Rathmacher J.A., Nissen S., Panton L., et al. Supplemen tation with a Combination of β- HydroxyβMethylbutyrate (HMB), Arginine, and Glutamine Is Safe and Could Improve Hematological Parameters. JPEN J Parenter Enteral Nutr. 2004 Mar-Apr;28(2):65–75. doi: 10.1177/014860710402800265.Berk L., James J., Schwartz A., Hug E., Mahadevan A., Samuels M., Kachnic L.; RTOG. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl betamethyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008 Oct;16(10):1179–88. doi: 10.1007/s00520–008–0403–7.Berk L., James J., Schwartz A., Hug E., Mahadevan A., Samuels M., Kachnic L.; RTOG. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl betamethyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008 Oct;16(10):1179–88. doi: 10.1007/s00520–008–0403–7.Liu K.A., Lashinger L. M., Rasmussen A. J., Hursting S. D. Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab. 2014 Mar 31;2(1):6. doi: 10.1186/2049–3002–2–6.Liu K.A., Lashinger L. M., Rasmussen A. J., Hursting S. D. Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab. 2014 Mar 31;2(1):6. doi: 10.1186/2049–3002–2–6.Hunter D.C., Weintraub M., Blackburn G. L., Bistrian B. R. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg. 1989 Feb;76(2):149–53. doi: 10.1002/bjs.1800760215.Hunter D.C., Weintraub M., Blackburn G. L., Bistrian B. R. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg. 1989 Feb;76(2):149–53. doi: 10.1002/bjs.1800760215.Szefel J., Kruszewski W. J., Ciesielski M., et al. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. Oncol Rep. 2012 Jul;28(1):319–23. doi: 10.3892/or.2012.1804.Szefel J., Kruszewski W. J., Ciesielski M., et al. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. Oncol Rep. 2012 Jul;28(1):319–23. doi: 10.3892/or.2012.1804.Cruciani R.A., Dvorkin E., Homel P., et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004 Nov;1033:168–76. doi: 10.1196/annals.1320.016.Cruciani R.A., Dvorkin E., Homel P., et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004 Nov;1033:168–76. doi: 10.1196/annals.1320.016.Cruciani R.A., Dvorkin E., Homel P., et al. Safety, Tolerability and Symptom Outcomes Associated with l- Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase I/II Study. J Pain Symptom Manage. 2006 Dec;32(6):551–9. doi: 10.1016/j.jpainsymman.2006.09.001.Cruciani R.A., Dvorkin E., Homel P., et al. Safety, Tolerability and Symptom Outcomes Associated with l- Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase I/II Study. J Pain Symptom Manage. 2006 Dec;32(6):551–9. doi: 10.1016/j.jpainsymman.2006.09.001.Gramignano G., Lusso M. R., Madeddu C., et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006 Feb;22(2):136–45. doi: 10.1016/j.nut.2005.06.003.Gramignano G., Lusso M. R., Madeddu C., et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006 Feb;22(2):136–45. doi: 10.1016/j.nut.2005.06.003.Kraft M., Kraft K., Gärtner S., et al. L–Carnitine-supplementation in advanced pancreatic cancer (CARPAN) A randomized multicentre trial. Nutr J. 2012 Jul 23;11:52. doi: 10.1186/1475–2891–11–52.Kraft M., Kraft K., Gärtner S., et al. L–Carnitine-supplementation in advanced pancreatic cancer (CARPAN) A randomized multicentre trial. Nutr J. 2012 Jul 23;11:52. doi: 10.1186/1475–2891–11–52.Cruciani R.A., Dvorkin E., Homel P., Culliney B., Malamud S., Lapin J., et al. L–Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study. J Pain Symptom Manage. 2009 Apr;37(4):622–31. doi: 10.1016/j.jpainsymman.2008.03.021.Cruciani R.A., Dvorkin E., Homel P., Culliney B., Malamud S., Lapin J., et al. L–Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study. J Pain Symptom Manage. 2009 Apr;37(4):622–31. doi: 10.1016/j.jpainsymman.2008.03.021.Cruciani R.A., Zhang J. J., Manola J., Cella D., Ansari B., Fisch M. J. L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012 Nov 1;30(31):3864–9. doi: 10.1200/JCO.2011.40.2180.Cruciani R.A., Zhang J. J., Manola J., Cella D., Ansari B., Fisch M. J. L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012 Nov 1;30(31):3864–9. doi: 10.1200/JCO.2011.40.2180.

The authors declare that there are no conflicts of interest present.